2648260-80-2
2648260-80-2
Chemical Structure
Rademikibart
Synonym(s): CBP-201
- CAS No.: 2648260-80-2
- Formula:N/A
- Molecular Weight:(145.36 kDa)
SMILES: [Rademikibart]
Biological Activity: Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rademikibart | 99.13% | Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang J, et al. Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023 Dec;16(12):2614-2627. [Content Brief]
-
[2]. Collazo, et al. Rapid Improvement in Lung Function Observed With Rademikibart in Patients With Moderate-to-Severe Uncontrolled Asthma. AJRCCM. 2025 May 01;211(Supplement_1):A5041.
-
[3]. Collazo, et al. Effect of Rademikibart on Blood Eosinophil Counts in Patients With
Asthma: Is There an IL-4Rα Class Effect? AJRCCM. 2025 May 01;211(Supplement_1):A1339.
Keywords
